Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ganymed Pharmaceuticals AG

http://www.ganymed-pharmaceuticals.de/

Latest From Ganymed Pharmaceuticals AG

Astellas Reports Second Phase III Win With Zolbetuximab In Stomach Cancer

The anti-Claudin-18.2 agent plus chemotherapy improves progression-free survival in inoperable or metastatic stomach cancer, following a similar Phase III readout in November.

Clinical Trials Business Strategies

Astellas's First-In-Class CLDN18 Antibody Meets Phase III Gastric Endpoints

Novel candidate acquired from Ganymed in 2016 moves closer to first approval filing anywhere for a CLDN18-targeting antibody, and as a potential competitor for Opdivo in HER2-negative gastric cancer, following positive top-line Phase III results in the first-line combo setting. Results from GLOW trial in combination with CAPOX also awaited.

Cancer Clinical Trials

Appointments: Celgene, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector And Axcella Health Announce New Hires

Companies announcing executives moves this week include Celgene with a new CFO, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector, Axcella Health, and NDA Group. The British Generic Manufacturers Association also announced a new chair.

Executive Changes BioPharmaceutical

Biopharma Quarterly Dealmaking Statistics, Q4 2016

Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.

BioPharmaceutical Deals
See All

Company Information

UsernamePublicRestriction

Register